Genetic variations underlying Alzheimer's disease: Evidence from genome-wide association studies and beyond

The Lancet Neurology

Volumn 15, Issue 8, 2016, Pages 857-868

  Cuyvers, Elise ^a,b   Sleegers, Kristel ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; TREM2 PROTEIN, HUMAN;

ALZHEIMER DISEASE; COMPARATIVE STUDY; COPY NUMBER VARIATION; DIAGNOSTIC ACCURACY; GENE IDENTIFICATION; GENE LOCUS; GENETIC RISK; GENETIC SCREENING; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HERITABILITY; HUMAN; NEXT GENERATION SEQUENCING; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; GENETIC PREDISPOSITION; GENETICS;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MEMBRANE GLYCOPROTEINS; RECEPTORS, IMMUNOLOGIC;

EID: 84973308454     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)00127-7     Document Type: Review

References (108)

1. World Alzheimer report 2015: the global impact of dementia, an analysis of prevalence, incidence, costs and trends 2015, Alzheimer's Disease International, Alzheimer's Disease International, London.
2. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:263-269.
3. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014, 13:614-629.
4. Braak H, Braak E Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
5. World Alzheimer report 2014: dementia and risk reduction, an analysis of protective and modifiable factors 2014, Alzheimer's Disease International, Alzheimer's Disease International, London.
6. Brouwers N, Sleegers K, Van Broeckhoven C Molecular genetics of Alzheimer's disease: an update. Ann Med 2008, 40:562-583.
7. Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL Early-onset Alzheimer's disease is associated with greater pathologic burden. J Geriatr Psychiatry Neurol 2007, 20:29-33.
8. Jarmolowicz AI, Chen HY, Panegyres PK The patterns of inheritance in early-onset dementia: Alzheimer's disease and frontotemporal dementia. Am J Alzheimers Dis Other Demen 2014, 30:299-306.
9. Wallon D, Rousseau S, Rovelet-Lecrux A, et al. The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J Alzheimers Dis 2012, 30:847-856.
10. Liddell MB, Lovestone S, Owen MJ Genetic risk of Alzheimer's disease: advising relatives. Br J Psychiatry 2001, 178:7-11.
11. van Duijn CM, Clayton D, Chandra V, et al. Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991, 20(suppl 2):S13-S20.
12. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009, 41:1088-1093.
13. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011, 43:429-435.
14. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009, 41:1094-1099.
15. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011, 43:436-441.
16. Seshadri S, Fitzpatrick AL, Ikram MA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010, 303:1832-1840.
17. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013, 45:1452-1458.
18. Bertram L, Lange C, Mullin K, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 2008, 83:623-632.
19. Bettens K, Sleegers K, van Broeckhoven C Genetic insights in Alzheimer's disease. Lancet Neurol 2013, 12:92-104.
20. Karch CM, Goate AM Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 2015, 77:43-51.
21. Morgan K The three new pathways leading to Alzheimer's disease. Neuropathol Appl Neurobiol 2011, 37:353-357.
22. Saykin JS, Shen L, Yao X, et al. Genetic studies of quantitative MCI and AD phenotypes in ADNI: progress, opportunities and plans. Alzheimers Dement 2015, 11:792-814.
23. Humphries C, Kohli MA, Whitehead P, Mash DC, Pericak-Vance MA, Gilbert J Alzheimer disease (AD) specific transcription, DNA methylation and splicing in twenty AD associated loci. Mol Cell Neurosci 2015, 67:37-45.
24. Shulman JM, Imboywa S, Giagtzoglou N, et al. Functional screening in Drosophila identifies Alzheimer's disease susceptibility genes and implicates Tau-mediated mechanisms. Hum Mol Genet 2014, 23:870-877.
25. Edwards SL, Beesley J, French JD, Dunning AM Beyond GWASs: illuminating the dark road from association to function. Am J Hum Genet 2013, 93:779-797.
26. Bell RD, Sagare AP, Friedman AE, et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2007, 27:909-918.
27. Bettens K, Brouwers N, Engelborghs S, et al. Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Mol Neurodegener 2012, 7:3.
28. Rosenthal SL, Barmada MM, Wang X, Demirci FY, Kamboh MI Connecting the dots: potential of data integration to identify regulatory SNPs in late-onset Alzheimer's disease GWAS findings. PLoS One 2014, 9:e95152.
29. Szymanski M, Wang R, Bassett SS, Avramopoulos D Alzheimer's risk variants in the Clusterin gene are associated with alternative splicing. Transl Psychiatry 2011, 1:e18.
30. Nilselid AM, Davidsson P, Nagga K, Andreasen N, Fredman P, Blennow K Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int 2006, 48:718-728.
31. Schurmann B, Wiese B, Bickel H, et al. Association of the Alzheimer's disease clusterin risk allele with plasma clusterin concentration. J Alzheimers Dis 2011, 25:421-424.
32. Thambisetty M, Simmons A, Velayudhan L, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 2010, 67:739-748.
33. Tan MS, Yu JT, Tan L Bridging integrator 1 (BIN1): form, function, and Alzheimer's disease. Trends Mol Med 2013, 19:594-603.
34. Chapuis J, Hansmannel F, Gistelinck M, et al. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol Psychiatry 2013, 18:1225-1234.
35. Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol 1999, 29:3440-3449.
36. Malik M, Simpson JF, Parikh I, et al. CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing. J Neurosci 2013, 33:13320-13325.
37. Raj T, Ryan KJ, Replogle JM, et al. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility. Hum Mol Genet 2014, 23:2729-2736.
38. Griciuc A, Serrano-Pozo A, Parrado AR, et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013, 78:631-643.
39. Brouwers N, Van Cauwenberghe C, Engelborghs S, et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol Psychiatry 2011, 17:223-233.
40. Szigeti K, Lal D, Li Y, et al. Genome-wide scan for copy number variation association with age at onset of Alzheimer's disease. J Alzheimers Dis 2013, 33:517-523.
41. Keenan BT, Shulman JM, Chibnik LB, et al. A coding variant in CR1 interacts with APOE-epsilon4 to influence cognitive decline. Hum Mol Genet 2012, 21:2377-2388.
42. Van Cauwenberghe C, Bettens K, Engelborghs S, et al. CR1 coding variant p.Ser1610Thr in Alzheimer disease and related endophenotypes. Neurobiol Aging 2013, 34:2235.e1-2235.e6.
43. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007, 39:168-177.
44. Miyashita A, Koike A, Jun G, et al. SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians. PLoS One 2013, 8:e58618.
45. Bohm C, Seibel NM, Henkel B, Steiner H, Haass C, Hampe W SorLA signaling by regulated intramembrane proteolysis. J Biol Chem 2006, 281:14547-14553.
46. Lintzel J, Franke I, Riedel IB, Schaller HC, Hampe W Characterization of the VPS10 domain of SorLA/LR11 as binding site for the neuropeptide HA. Biol Chem 2002, 383:1727-1733.
47. Vardarajan BN, Zhang Y, Lee JH, et al. Coding mutations in SORL1 and Alzheimer disease. Ann Neurol 2015, 77:215-227.
48. Reitz C, Jun G, Naj A, et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ε4, and the risk of late-onset Alzheimer disease in African Americans. JAMA 2013, 309:1483-1492.
49. Cukier HN, Kunkle BW, Rolati S, et al. ABCA7 deletion associated with Alzheimer's disease in African Americans. Alzheimers Dement 2015, 11(suppl):P485-P486. for the Alzheimer Disease Genetics Consortium.
50. Cuyvers E, De Roeck A, Van den Bossche T, et al. Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study. Lancet Neurol 2015, 14:814-822.
51. Steinberg S, Stefansson H, Jonsson T, et al. Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. Nat Genet 2015, 47:445-447.
52. Vardarajan BN, Ghani M, Kahn A, et al. Rare coding mutations identified by sequencing of Alzheimer disease genome-wide association studies loci. Ann Neurol 2015, 78:487-498.
53. Witte JS, Visscher PM, Wray NR The contribution of genetic variants to disease depends on the ruler. Nat Rev Genet 2014, 15:765-776.
54. Ridge PG, Mukherjee S, Crane PK, Kauwe JS Alzheimer's disease: analyzing the missing heritability. PLoS One 2013, 8:e79771.
55. Lee SH, Harold D, Nyholt DR, et al. Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis. Hum Mol Genet 2013, 22:832-841.
56. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006, 63:168-174.
57. Lee SH, Wray NR, Goddard ME, Visscher PM Estimating missing heritability for disease from genome-wide association studies. Am J Hum Genet 2011, 88:294-305.
58. Seshadri S, Wolf PA Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. Lancet Neurol 2007, 6:1106-1114.
59. Genin E, Hannequin D, Wallon D, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011, 16:903-907.
60. Cuyvers E, Bettens K, Philtjens S, et al. Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging 2014, 35:726-729.
61. INDI-V: Various measures that quantify the contribution of individual independent disease risk variants The Centre for Neurogenetics and Statistical Genomics, (accessed May 12, 2016). http://cnsgenomics.com/shiny/INDI-V/.
62. Kunkle B, Grenier-Boley B, Vronskaya M, et al. Low-frequency variant imputation identifies rare variant candidate loci in a GWAS of late-onset Alzheimer disease in the IGAP Consortium. Alzheimers Dement 2015, 11(suppl):P333-P334. for The International Genomics of Alzheimer's Project (IGAP).
63. Verhaaren BF, Vernooij MW, Koudstaal PJ, et al. Alzheimer's disease genes and cognition in the nondemented general population. Biol Psychiatry 2013, 73:429-434.
64. Ebbert MT, Ridge PG, Wilson AR, et al. Population-based analysis of Alzheimer's disease risk alleles implicates genetic interactions. Biol Psychiatry 2014, 75:732-737.
65. Bansal V, Libiger O, Torkamani A, Schork NJ Statistical analysis strategies for association studies involving rare variants. Nat Rev Genet 2010, 11:773-783.
66. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013, 368:117-127.
67. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013, 368:107-116.
68. Lue LF, Schmitz C, Walker DG What happens to microglial TREM2 in Alzheimer's disease: immunoregulatory turned into immunopathogenic?. Neuroscience 2015, 302:138-150.
69. Kleinberger G, Yamanishi Y, Suarez-Calvet M, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 2014, 6:243ra86.
70. Ulrich JD, Finn MB, Wang Y, et al. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener 2014, 9:20.
71. Pottier C, Hannequin D, Coutant S, et al. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry 2012, 17:875-879.
72. Nicolas G, Charbonnier C, Wallon D, et al. SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. Mol Psychiatry 2016, 21:831-836.
73. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488:96-99.
74. Giraldo M, Lopera F, Siniard AL, et al. Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease. Neurobiol Aging 2013, 34:2077.e11-2077.e18.
75. Benitez BA, Cooper B, Pastor P, et al. TREM2 is associated with the risk of Alzheimer's disease in Spanish population. Neurobiol Aging 2013, 34:1711.e15-1711.e17.
76. Pottier C, Wallon D, Rousseau S, et al. TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease. J Alzheimers Dis 2013, 35:45-49.
77. Cruchaga C, Karch CM, Jin SC, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature 2014, 505:550-554.
78. Lambert JC, Grenier-Boley B, Bellenguez C, et al. PLD3 and sporadic Alzheimer's disease risk. Nature 2015, 520:E1.
79. Heilmann S, Drichel D, Clarimon J, et al. PLD3 in non-familial Alzheimer's disease. Nature 2015, 520:E3-E5.
80. Hooli BV, Lill CM, Mullin K, et al. PLD3 gene variants and Alzheimer's disease. Nature 2015, 520:E7-E8.
81. van der Lee SJ, Holstege H, Wong TH, et al. PLD3 variants in population studies. Nature 2015, 520:E2-E3.
82. Wang LS, Naj AC, Graham RR, et al. Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol 2015, 72:209-216.
83. Bamne MN, Demirci FY, Berman S, et al. Investigation of an amyloid precursor protein protective mutation (A673T) in a North American case-control sample of late-onset Alzheimer's disease. Neurobiol Aging 2014, 35:1779.e15-1779.e16.
84. Liu YW, He YH, Zhang YX, et al. Absence of A673T variant in APP gene indicates an alternative protective mechanism contributing to longevity in Chinese individuals. Neurobiol Aging 2014, 35:935.e11-935.e12.
85. Kero M, Paetau A, Polvikoski T, et al. Amyloid precursor protein (APP) A673T mutation in the elderly Finnish population. Neurobiol Aging 2013, 34:1518.e1-1518.e3.
86. Wilson MR, Easterbrook-Smith SB Clusterin is a secreted mammalian chaperone. Trends Biochem Sci 2000, 25:95-98.
87. Bettens K, Vermeulen S, Van Cauwenberghe C, et al. Reduced secreted clusterin as a mechanism for Alzheimer-associated CLU mutations. Mol Neurodegener 2015, 10:30.
88. Caglayan S, Takagi-Niidome S, Liao F, et al. Lysosomal sorting of amyloid-beta by the SORLA receptor is impaired by a familial Alzheimer's disease mutation. Sci Transl Med 2014, 6:223ra20.
89. Satoh K, Abe-Dohmae S, Yokoyama S, St George-Hyslop P, Fraser PE ATP-binding cassette transporter A7 (ABCA7) loss of function alters Alzheimer amyloid processing. J Biol Chem 2015, 290:24152-24165.
90. Korvatska O, Leverenz JB, Jayadev S, et al. R47H variant of TREM2 associated with Alzheimer disease in a large late-onset family: clinical, genetic, and neuropathological study. JAMA Neurol 2015, 72:920-927.
91. Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet 2013, 9:e1003709.
92. Plenge RM, Scolnick EM, Altshuler D Validating therapeutic targets through human genetics. Nat Rev Drug Discov 2013, 12:581-594.
93. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015, 372:1489-1499. for the ODYSSEY LONG TERM Investigators.
94. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015, 372:1500-1509. for the Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators.
95. Malik M, Chiles J, Xi HS, et al. Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia. Hum Mol Genet 2015, 24:3557-3570.
96. Clinical utility of genetic and genomic services: a position statement of the American College of Medical Genetics and Genomics. Genet Med 2015, 17:505-507. American College of Medical Genetics and Genomics Board of Directors.
97. Mills SM, Mallmann J, Santacruz AM, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris) 2013, 169:737-743.
98. Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011, 26(suppl 3):321-329.
99. Goldman JS, Hahn SE, Catania JW, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 2011, 13:597-605.
100. Rodriguez-Rodriguez E, Sanchez-Juan P, Vazquez-Higuera JL, et al. Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer's disease. J Neural Transm 2013, 120:807-812.
101. Martiskainen H, Helisalmi S, Viswanathan J, et al. Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach. J Alzheimers Dis 2015, 43:565-573.
102. Sleegers K, Bettens K, De Roeck A, et al. A 22-single nucleotide polymorphism Alzheimer risk score correlates with family history, onset age, and cerebrospinal fluid Abeta. Alzheimers Dement 2015, 11:1452-1460.
103. Chauhan G, Adams HH, Bis JC, et al. Association of Alzheimer's disease GWAS loci with MRI markers of brain aging. Neurobiol Aging 2015, 36:1765.e7-1765.e16.
104. Kong D, Giovanello KS, Wang Y, et al. Predicting Alzheimer's disease using combined imaging-whole genome SNP data. J Alzheimers Dis 2015, 46:695-702.
105. Mihaescu R, Pencina MJ, Alonso A, et al. Incremental value of rare genetic variants for the prediction of multifactorial diseases. Genome Med 2013, 5:76.
106. Kosik KS Personalized medicine for effective Alzheimer disease treatment. JAMA Neurol 2015, 72:497-498.
107. Montine TJ, Montine KS Precision medicine: clarity for the clinical and biological complexity of Alzheimer's and Parkinson's diseases. J Exp Med 2015, 212:601-605.
108. Stessman HA, Bernier R, Eichler EE A genotype-first approach to defining the subtypes of a complex disease. Cell 2014, 156:872-877.